COMBINING CREATININE-BASED eGFR WITH CYSTATIN C-BASED EGFR TO BETTER ASSESS RENAL FUNCTION IN PATIENTS WITH DIABETES AND CHRONIC KIDNEY DISEASE 3A: IMPLICATIONS FOR DRUG SELECTION AND DOSAGE IN TYPE 2 DIABETES.
Daniel
D
Einhorn
Christian W
CW
Mende
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002755:Choice Behavior; D003404:Creatinine / Q000032:analysis* / Q000097:blood; D055316:Cystatin C / Q000032:analysis* / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D054796:Drug Dosage Calculations; D005260:Female; D005919:Glomerular Filtration Rate / Q000502:physiology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007677:Kidney Function Tests / Q000379:methods*; D008297:Male; D008875:Middle Aged; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology
D055316:Cystatin C; D007004:Hypoglycemic Agents; D003404:Creatinine